On October 20, Twist Bioscience Corp rose 5.43% in Regular Trading, trading at $147.36 per share, with turnover of $112 million.
The move coincided with renewed market attention following a disclosed position change involving Laponis Adam, which had already emerged as a recent public event catalyst for the stock.
Background context shows the company had been under valuation debate after recent coverage initiations remained cautious: Jefferies started coverage with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 target. Earlier, Twist Bioscience also announced an agreement to provide antibody characterization data services to Eli Lilly's TuneLab platform, highlighting ongoing commercial activity in its synthetic DNA and antibody discovery-related business. Taken together, the latest rise appears tied primarily to attention recovery after the position change disclosure following the prior sharp pullback.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)